Cell News and Research

RSS

Study demonstrates successful use of fat cells to support prolonged growth of human hematopoietic stem cells

One of the main obstacles that stands in the way of using human hematopoietic stem cells (hHSCs) to treat a variety of diseases is the difficulty growing them in culture—they quickly die or differentiate into other cell types. A series of experiments that demonstrate the successful use of fat cells as part of a feeder layer to support prolonged growth of hHSCs in culture is reported in an article in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers.

11 Apr 2013

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Deep inside your brain, a legion of stem cells lies ready to turn into new brain and nerve cells whenever and wherever you need them most. While they wait, they keep themselves in a state of perpetual readiness - poised to become any type of nerve cell you might need as your cells age or get damaged.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

CanCELL cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line answers identified market needs in oncology research and drug discovery.

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

Computational simulations can help understand, treat cardiac rhythm disorders

Computational models of the human heart can be very useful in studying not just the basic mechanisms of heart function, but also to analyze the heart in a diseased state, and come up with methods for diagnosis and therapy.

11 Apr 2013

Reduction in neurogenesis associated with loss of certain cognitive faculties

These results incentivise the development of targeted therapies enabling improved neurone production to alleviate cognitive decline in the elderly and reduce the cerebral lesions caused by radiotherapy.

11 Apr 2013

New research finds HPV plays role in lung cancer in some patients

A common virus known to cause cervical and head and neck cancers may also trigger some cases of lung cancer, according to new research presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Wednesday, April 10.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation

Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration for the potential treatment of patients with breast cancer.

From Pfizer, Inc. 11 Apr 2013

Cell News and Research

Study demonstrates successful use of fat cells to support prolonged growth of human hematopoietic stem cells

New research reveals how autophagy keeps neural stem cells to replace damaged brain, nerve cells

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Cellectis CanCELL cell lines enable drug positioning in cancer pathways

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Computational simulations can help understand, treat cardiac rhythm disorders

Reduction in neurogenesis associated with loss of certain cognitive faculties

New research finds HPV plays role in lung cancer in some patients

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

FDA accepts Merck's NDA for NOXAFIL tablets

Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation

Data on PV-10 combination therapy presented at AACR Annual Meeting

Research opens new avenue for treatment of melanoma

First-in-humans study introduces next generation cell therapy for heart failure patients

Doctors don't receive information about harmful effects of medicines during promotional visits

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics